---
title: Smooth medication wearing off swings
nct_id: NCT05916157
status: RECRUITING
sponsor: AbbVie
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05916157"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05916157"
last_fetched: "2026-05-10T14:07:16.845Z"
source: "Parkinson's Pathways (curated)"
---
# Smooth medication wearing off swings

**Goal (in five words):** Smooth medication wearing off swings

**Official Title:** A Post-marketing Observational Study for ABBV-951 in Patients Diagnosed With Advanced Parkinson's Disease (aPD)

**Trial ID:** [NCT05916157](https://clinicaltrials.gov/study/NCT05916157)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** AbbVie
- **Target Enrollment:** 250 participants
- **Start Date:** 2023-11-30
- **Completion Date:** 2026-07
- **Conditions:** Parkinson's Disease (PD)

## Summary For Families

The goal is to track how ABBV-951 performs in everyday care for people with advanced Parkinson's, looking at real-world safety, how well it reduces off time, and whether it helps daily function. ABBV-951 is a prescribed medication that provides continuous dopaminergic stimulation by activating dopamine receptors, used alongside levodopa to smooth out the on/off swings that happen as levodopa wears off. The study follows patients who are newly prescribed ABBV-951 by their doctor, includes people aged 15 and up with advanced PD who consent to participate, and excludes anyone who has already used ABBV-951 or is in another interventional trial.

## Eligibility

- **Minimum age:** 15 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Diagnosed with advanced Parkinson's disease (aPD).
* Prescribed ABBV-951 as physicians' decision according to the approved label for treatment of aPD.
* Given informed consent (or by her/his legal representative, if it's a requirement from the participating hospital/clinic) for participating this study.

Exclusion Criteria:

* Prior treatment with ABBV-951 for PD.
* Currently participating in interventional clinical trials.
```

## Locations (16)

- Saiseikai Matsuyama Hospital /ID# 276259, Matsuyama, Ehime, Japan _(33.8392, 132.7657)_
- National Hospital Organization Asahikawa Medical Center /ID# 269115, Asahikawa, Hokkaido, Japan _(43.7706, 142.3649)_
- Ryugasaki Saiseikai Hospital /ID# 264435, Ryūgasaki, Ibaraki, Japan _(35.9000, 140.1833)_
- University of Tsukuba Hospital /ID# 268353, Tsukuba, Ibaraki, Japan _(36.0833, 140.1167)_
- Okatsu Hospital /ID# 262781, Kagoshima, Kagoshima-ken, Japan _(31.5667, 130.5500)_
- University Hospital Kyoto Prefectural University of Medicine /ID# 267445, Kyoto, Kyoto, Japan _(35.0211, 135.7538)_
- Sendai Nishitaga National Hospital /ID# 268349, Sendai, Miyagi, Japan _(38.2667, 140.8667)_
- Fujimoto General Hospital /ID# 277287, Miyakonojo-shi, Miyazaki, Japan
- Shiga University of Medical Science Hospital /ID# 265637, Ōtsu, Shiga, Japan _(35.0000, 135.8667)_
- Dokkyo Medical University Hospital /ID# 269116, Mibu, Tochigi, Japan _(36.4167, 139.8000)_
- Juntendo University Hospital /ID# 264438, Bunkyo-ku, Tokyo, Japan
- Nitobe Memorial Nakano General Hospital /ID# 275668, Nakano-ku, Tokyo, Japan
- National Center of Neurology and Psychiatry - Kodaira /ID# 267372, Xiaoping City, Tokyo, Japan
- National Hospital Organization Utano Hospital /ID# 268350, Kyoto, Japan _(35.0211, 135.7538)_
- Okayama Neurology Clinic /ID# 269117, Okayama, Japan _(34.6500, 133.9333)_
- Municipal Toyonaka Hospital /ID# 271277, Toyonaka, Japan _(34.7824, 135.4693)_

## Central Contacts

- AbbVie GK Clinical Trial Registration Desk — (CONTACT) — +81-3-4577-1111 — abbvie_jpn_info_clingov@abbvie.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT05916157*  
*HTML version: https://parkinsonspathways.com/trial/NCT05916157*  
*Source data: https://clinicaltrials.gov/study/NCT05916157*